Home
Editorial Board
Submit article
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Open Access
Purchase Single Articles
Archive
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
Subscribe
FAQ
Contact Us
Indian Journal of Genetics and Molecular Research

Volume  1, Issue 1, January - June 2012, Pages 7-7

 

Original Article

Medical Biotechnology and the Challenge of Chronic disease
B.S. Ramakrishna
Christian Medical College, Vellore
Choose an option to locate / access this Article:
Check if you have access through your login credentials.             |
|


Abstract

  The field of Medical Biotechnology has changed our lives in the 21st century to a great extent in understanding our genome, proteome, metabolome, microbiome, pharmacogenomics, nutrigenomics, nanomedicine, regenerative medicine and so on and so forth. Though the cutting edge technologies are available for diagnostics and therapy, chronic diseases remain a challenging. In India chronic diseases are projected to account for 53% of all deaths. World Health Organization (WHO) projects that in India over the next 10 years more than 60 million people will die from a chronic disease and deaths from infectious diseases, maternal and perinatal conditions, and nutritional deficiencies combined will decrease by 15%. However, the deaths from chronic diseases will increase by 18%.One such chronic disease is Crohn’s disease which causes chronic inflammation of the intestine. It is caused by an abnormal innate immune reaction to intestinal bacteria in an individual of the appropriate genetic makeup. At Christian Medical College, Vellore, over a period of two decades number of cases diagnosed with Crohn’s disease is comparatively higher than that of TB. TLRs and NOD receptor are two receptor families determine the balance between tolerance and inflammation. NOD2 mutations are associated with ileal crohn’s disease in Western countries. Whereas those common NOD2 mutations (R702W, G908R, F1007S) are lacking in Indian patients. Also, known Single Nucleotide Polymorphism (SNPs) in Heat Shock  Protein 70, Tumor Necrosis Factor alpha promoter, IL23 receptors are not found in Indian patients with Crohn’s disease. Hence, based on the prior experience in immunopathology of the disease, our group has been working on identifying a unique immune footprint for Crohn’s disease in Indians. Using the model of inflammatory bowel disease in Indians, this talk attempts to show how focused research may provide clues that can be translated to therapy or to public health measures that treat or prevent diseases. 


Corresponding Author : B.S. Ramakrishna